Invitrogen and Wiley Partner to Offer Selected Current Protocols™ Online; Collaboration Provides Free Access to the Best Lab Methods Available Through New iProtocol™ Website

Business Wire, Dec 12, 2005

SAN FRANCISCO -- Invitrogen Corporation (Nasdaq:IVGN), a leading life sciences company with a broad portfolio of technologies to improve and accelerate biomedical research, drug discovery and commercial bioproduction, today announced the introduction of iProtocol(TM), its latest technology and eScience contribution to the life sciences. Through a partnership with the global publisher John Wiley & Sons, Inc. (NYSE:JWa) (NYSE:JWb), scientists will have free access to selected Current Protocols(TM), which is the life science community's gold standard for lab research manuals.

iProtocol(TM) will provide selected content from Current Protocols(TM) titles starting with the most basic to the most advanced methods for Molecular Biology, Cell Biology, Immunology and Neuroscience. Bringing together protocols with supporting documentation, as well as required reagents, is another step towards standardization of common research workflows and expanded access to knowledge from scientists world-wide. The launch of iProtocol(TM), along with recently-introduced iPath(TM) and Vector NTI(R) Advance(TM) 10, reflect Invitrogen's continuing effort to rationalize and systematize products around the life science workflows in which they are used.

"Accelerating scientific discovery requires access to the best laboratory protocols in the world," said Greg Lucier, Chairman and CEO of Invitrogen Corporation. "Our agreement with Wiley makes it possible for iProtocol(TM) to ensure that scientists have access to a comprehensive collection of classic and cutting-edge methods used across the spectrum of biological research. Basic research and drug discovery efforts can proceed more rapidly now that the scientific community has access to proven techniques in these lab manuals through iProtocol(TM)."

"Broadening information access for researchers, scholars and practitioners is a critical mission for Wiley, and our partnership with Invitrogen facilitates that objective. What makes iProtocol(TM) even more valuable is that it makes seamless navigation and discovery possible across a growing web of published resources. For example, its functionality linking our Current Protocols(TM) 'recipes' to ecommerce sources for the 'ingredients' makes this an invaluable tool for the bench scientist," said Joe Ingram, Vice President & Executive Publisher, Current Protocols, John Wiley & Sons, Inc.

Life scientists are challenged daily to find the best laboratory protocols. These best practices from leading scientists worldwide will help ensure Invitrogen customers design more successful, accurate experiments.

For more information, log on to www.invitrogen.com/iprotocol.> About Invitrogen

Invitrogen Corporation (Nasdaq:IVGN) provides products and services that support academic and government research institutions and pharmaceutical and biotech companies worldwide in their efforts to improve the human condition. The company provides essential life science technologies for disease research, drug discovery and commercial bioproduction. Invitrogen's own research and development efforts are focused on breakthrough innovation in all major areas of biological discovery, including functional genomics, proteomics, bioinformatics and cell biology -- placing Invitrogen's products in nearly every major laboratory in the world. Founded in 1987, Invitrogen is headquartered in Carlsbad, Calif., and conducts business in more than 70 countries around the world. The company globally employs approximately 4,800 scientists and other professionals and had revenues of more than $1 billion in 2004. For more information, visit www.invitrogen.com.

About John Wiley & Sons, Inc.

Founded in 1807, John Wiley & Sons, Inc., provides must-have content and services to customers worldwide. Its core businesses include scientific, technical and medical journals, encyclopedias, books, and online products and services; professional and consumer books and subscription services; and educational materials for undergraduate and graduate students and lifelong learners. Wiley has publishing, marketing and distribution centers in the United States, Canada, Europe, Asia and Australia. Wiley's Internet site can be accessed at http://www.wiley.com.

Event for Coverage

On Monday, December 12th, at 4 p.m., Invitrogen Chairman and CEO Greg Lucier and Joe Ingram, Vice President & Executive Publisher, Current Protocols, John Wiley & Sons, will be announcing the details of this industry-changing collaboration. Conference attendees will be encouraged to ask questions about the collaboration and Invitrogen's other eScience initiatives, including Vector NTI(R) Advance(TM) 10 and iPath(TM). The event will take place at the San Francisco Marriott located at 55 4th Street, Pacific Conference Room I, 4th floor, across from Moscone Center.

Safe Harbor Statement

Certain statements contained in this press release and in today's conference call are considered "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995, and it is Invitrogen's intent that such statements be protected by the safe harbor created thereby. Such statements include, but are not limited to, statements that: 1) scientists will have free access to selected Current Protocols, including titles starting with the most basic to the most advanced methods for Molecular Biology, Cell Biology, Immunology, and Neuroscience; 2) basic research and drug discovery efforts can proceed more rapidly; because scientists have access to a comprehensive collection of classic and cutting-edge methods used across the spectrum of biological research; and 3) iProtocol will be an invaluable tool for the bench scientist. Such forward-looking statements are subject to a number of risks, uncertainties and other factors that could cause actual results to differ materially from future results expressed or implied by such forward-looking statements. Potential risks and uncertainties include, but are not limited to a) not all content from Current Protocols may be available through iProtocol; b) scientists' use of iProtocol may not lead to increased productivity and speed for basic research; and c) iProtocol may not be accepted by some scientists, as well as other risks and uncertainties detailed from time to time in Invitrogen's Securities and Exchange Commission filings.